# Anika raises 2026 outlook as Q3 revenue grows 10%

> Anika Therapeutics reported higher third-quarter revenue, stronger Integrity demand and increased manufacturing throughput while lifting the lower end of its 2026 growth outlook.

Source page: https://stoqly.net/news/anika-q3-2026-guidance-integrity-growth

- **Published:** 2026-11-06T21:05:00+00:00
- **Section:** Quarterly results
- **Company:** Anika Therapeutics, Inc. (ANIK), https://stoqly.net/companies/anik.md

Anika Therapeutics reported third-quarter 2026 revenue of $30.6 million, up 10% from $27.8 million a year earlier. Commercial Channel revenue rose approximately 17% to $14.0 million, while OEM Channel revenue increased approximately 5% to $16.6 million.

The company said International viscosupplement revenue increased 19% year over year and Regenerative Solutions revenue rose 12%. Integrity revenue grew by more than 30% year over year, supported in part by larger implant sizes introduced since late 2025. Anika also said demand had exceeded forecasts and that unit volumes on its cross-link line were more than 50% above 2022 levels.

Anika raised the lower end of its 2026 total-company revenue-growth guidance to 6%–10%, from 5%–10% previously. It lifted OEM growth guidance to 5%–9% from 0%–5%, while lowering the Commercial Channel range to 9%–13% from 12%–18%. Adjusted EBITDA margin guidance increased to 15%–17% from 13%–17%.

The company said it secured a new 10-year Hyvisc partnership with improved economics and completed enrollment in its Cingal bioequivalence study. It also disclosed that the FDA had found the Hyalofast pre-market approval application not approvable in October and that it was evaluating regulatory next steps.

**Why it matters** Anika's quarter points to stronger demand for its regenerative products and a higher profitability floor, although the revised channel mix and Hyalofast regulatory setback remain important factors for the outlook.

- Q3 revenue: $30.6M +10% vs. Q3 2025
- Commercial Channel: $14.0M +17% year over year
- OEM Channel: $16.6M +5% year over year
- Cash: $45.0M at Sept. 30, 2026

- [Anika Reports Third Quarter 2026 Financial Results, Nov. 6, 2026](https://ir.anika.com/2026-11-06-Anika-Reports-Third-Quarter-2026-Financial-Results)
- [Anika Integrity implant product page](https://anika.com/products/regen/integrity/)

---

Written by Stoqly from SEC filings and market data. For information only — not investment advice or a recommendation to buy, sell or hold any security.